News

Assuming a comparable full year of OWYN results are included in fiscal year 2024, as well as the exclusion of the fifty-third week in fiscal year 2024, fiscal year 2025 is expected to be in line with ...
FDA Approves EGRIFTA WRâ„¢ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19 million, ...